2.05 (-%)
As of Oct 30, 2024
Source:
We are a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid drug conjugate ™ (PDC™) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects.
Country | United States |
Headquarters | florham park, new jersey |
Phone Number | (608) 441-8120 |
Industry | manufacturing |
CEO | James V. Caruso |
Website | www.cellectar.com |